Quarterly ResultAug 5, 2026, 04:03 PM
Biodesix Q2 Revenue $26.9M, Up 34%; Gross Margin 82%
AI Summary
Biodesix, Inc. announced strong financial and operating results for the second quarter ended June 30, 2026. The company delivered $26.9 million in total revenue, marking a 34% increase year-over-year, and achieved an 82% gross margin. Diagnostic Testing revenue grew 42%, driven by higher test volumes and improved average revenue per test. Biodesix also significantly improved its net loss and Adjusted EBITDA, while maintaining its full-year 2026 revenue guidance of $108-114 million.
Key Highlights
- Total revenue for Q2 2026 was $26.9 million, representing 34% growth year-over-year.
- Diagnostic Testing revenue grew 42% to $25.4 million, driven by a 38% increase in test volumes.
- Gross margin reached 82% in Q2 2026, a 200-basis point improvement from the prior year.
- Net loss for Q2 2026 improved by 37% to $7.3 million.
- Adjusted EBITDA loss improved by 56% to $3.2 million in Q2 2026.
- Maintained FY 2026 revenue guidance of $108-114 million, with the midpoint reflecting 25% growth.
- Cash and cash equivalents increased 17% to $30.0 million as of June 30, 2026.
Price Impact
More from BDSX